ABBVIE INC Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for ABBVIE INC, and when can generic versions of ABBVIE INC drugs launch?
ABBVIE INC has fourteen approved drugs.
There are seventy-six US patents protecting ABBVIE INC drugs.
There are one thousand three hundred and twenty-one patent family members on ABBVIE INC drugs in fifty-seven countries and one hundred and twenty-eight supplementary protection certificates in nineteen countries.
Summary for ABBVIE INC
| International Patents: | 1321 |
| US Patents: | 76 |
| Tradenames: | 13 |
| Ingredients: | 13 |
| NDAs: | 14 |
| Drug Master File Entries: | 15 |
| Patent Litigation for ABBVIE INC: | See patent lawsuits for ABBVIE INC |
Drugs and US Patents for ABBVIE INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Inc | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-003 | Apr 11, 2016 | RX | Yes | Yes | 11,110,087 | See Plans and Pricing | See Plans and Pricing | ||||
| Abbvie Inc | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-003 | Apr 11, 2016 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| Abbvie Inc | MAVYRET | glecaprevir; pibrentasvir | PELLETS;ORAL | 215110-001 | Jun 10, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| Abbvie Inc | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | No | 9,951,080 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Abbvie Inc | VUITY | pilocarpine hydrochloride | SOLUTION;OPHTHALMIC | 214028-001 | Oct 28, 2021 | RX | Yes | Yes | 10,610,518 | See Plans and Pricing | See Plans and Pricing | ||||
| Abbvie Inc | ORIAHNN (COPACKAGED) | elagolix sodium,estradiol,norethindrone acetate; elagolix sodium | CAPSULE;ORAL | 213388-001 | May 29, 2020 | RX | Yes | Yes | 7,056,927 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ABBVIE INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-001 | Sep 4, 2001 | 6,074,670 | See Plans and Pricing |
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | 6,703,403*PED | See Plans and Pricing |
| Abbvie Inc | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-001 | Jul 23, 2018 | 7,462,625 | See Plans and Pricing |
| Abbvie Inc | ORIAHNN (COPACKAGED) | elagolix sodium,estradiol,norethindrone acetate; elagolix sodium | CAPSULE;ORAL | 213388-001 | May 29, 2020 | 6,872,728 | See Plans and Pricing |
| Abbvie Inc | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-002 | Jul 23, 2018 | 6,872,728 | See Plans and Pricing |
| Abbvie Inc | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-001 | Jul 23, 2018 | 7,179,815 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ABBVIE INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2010-12-21 |
| ➤ Subscribe | Tablets | 48 mg | ➤ Subscribe | 2008-07-01 |
| ➤ Subscribe | Capsules | 100 mg | ➤ Subscribe | 2012-10-31 |
| ➤ Subscribe | Tablets | 145 mg | ➤ Subscribe | 2007-10-19 |
International Patents for ABBVIE INC Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20140032338 | See Plans and Pricing |
| Lithuania | C2368890 | See Plans and Pricing |
| Taiwan | 201107323 | See Plans and Pricing |
| Poland | 2468287 | See Plans and Pricing |
| World Intellectual Property Organization (WIPO) | 2009152133 | See Plans and Pricing |
| Taiwan | I449703 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ABBVIE INC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2340029 | 32/2015 | Austria | See Plans and Pricing | PRODUCT NAME: PARITAPREVIR, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER ANNEHMBARER ESTER DAVON; REGISTRATION NO/DATE: (MITTEILUNG VOM 19.1.2015) EU/1/14/982 20150115 |
| 2435432 | PA2017015 | Lithuania | See Plans and Pricing | PRODUCT NAME: VENETOKLAKSAS; REGISTRATION NO/DATE: EU/1/16/1138 20161205 |
| 2203431 | CR 2015 00014 | Denmark | See Plans and Pricing | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119 |
| 2340029 | CA 2015 00013 | Denmark | See Plans and Pricing | PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEROF; REG. NO/DATE: EU/1/14/982 20150115 |
| 2506716 | 20C1009 | France | See Plans and Pricing | PRODUCT NAME: UPADACITINIB OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/19/1404 20191218 |
| 2435432 | CR 2017 00021 | Denmark | See Plans and Pricing | PRODUCT NAME: VENETOCLAX; REG. NO/DATE: EU/1/16/1138/001-007 20161207 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
